LONDON
The global market for central nervous system (CNS) therapeutics is forecast to be worth USD 133bn by end-2018. The growth will be chiefly fuelled by an increase in disease prevalence rates owing to the globe’s ageing population, launch of a novel class of drugs, and increased healthcare spending. The United States is the largest regional CNS market, whereas the Asia-Pacific market’s revenues are growing at the fastest rate (about 6% CAGR over the forecast period). Anti-epilepsy drugs are the most rapidly evolving product market.
However, the CNS therapeutics market presently keeps on experiencing certain challenges due to the continual patent expiration of brand-name drugs from various big companies, like Johnson & Johnson, UCB, Pfizer, and GlaxoSmithKline, among others. In the next decade, the market is expected to face enormous pressure due to severe generic erosion as multimillion-dollar drugs by annual sales fall under momentary price pressures. Moreover, branded drug makers will be troubled by healthcare cost rationing and government caps.
Insightful report “CNS Therapeutics: Market Research Report” elaborated by Global Industry Analysts provides an in-depth analysis of the global CNS therapeutics market by the major product groups, such as anti-Alzheimer’s, anti-Parkinson’s, anti-epilepsy, pain management (includes migraine, nociceptive and neuropathic pain), anti-psychotics, anti-depressants, and others (includes multiple sclerosis, insomnia and ADHD). Separate annual market estimates (historical and current) and forecasts up to 2018 for the key geographical markets, such as the United States, Canada, Europe, the Asia-Pacific, Latin America, and RoW, are included. The study provides an all-round overview of the key trends and burning issues impacting the market, major growth drivers and restrains, the competitive landscape, M&As, and other strategic industry affairs. Furthermore, the research is supplemented with elaborate profiles of 127 leading and niche market participants.
Report Details:
Title: CNS Therapeutics: Market Research Report
Published: February, 2013
Pages: 1058
Price: US$ 4,950.00
http://marketpublishers.com/report/healthcare/therapy/cns-therapeutics_gia.html
Report Contents:
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
CNS Disorders
Anti-Alzheimer’s Drugs
Anti-Parkinson’s Drugs
Anti-Epilepsy Drugs
Pain Management Drugs
Anti-Psychotics Drugs
…
More insightful reports by Global Industry Analysts can be found at http://marketpublishers.com/members/gia/info.html
CONTACT
The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax:
+44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com